You are here: Industry Insights > Market News > Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist

firstwordpharmaJuly 12, 2021

Tag: Sputnik V , COVID-19 , mRNA vaccine , SARS-CoV-2

Favorites

Viral vector and mRNA vaccines, including Russia's Sputnik V, provide enough protection against the new Delta strain of the coronavirus, albeit to a lesser extent, reported The Times of India.

The observation was made by Sergey Netesov, head of the Novosibirsk State University's Laboratory and member of the Russian Academy of Sciences.

Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist

They offered 95% protection against the initial strain and now they give 90% protection against the Delta variant, Netesov said.

Sputnik V uses two different engineered adenoviruses (rAd26 and rAd5 for the first and second doses, respectively) to deliver the genetic code for the spike protein of SARS-CoV-2.

Previous:Unvaccinated Belgian woman contracted two COVID variants simultaneously

Next:Israeli co Bonus BioGroup reports Covid-19 treatment success

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>